Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023 ...Middle East

ORSERDU (elacestrant) was approved by the FDA in January 2023 for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with ESR1-mutations (ESR1-mut) that are found in up to 40% of tumors In patients whose tumors...

Hence then, the article about menarini group shares new analysis from emerald clinical study of orserdu elacestrant in metastatic breast cancer at asco 2023 was published today ( Friday 26/05/2023 - 02:00 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023 )

Also on site :

• Germany’s Merz changes stance on Russia
• Tokyo's Yamanote Line suspended due to power outage
• Germany’s Merz acknowledges ‘strategic mistake’